HHS rolled out a new $500 million initiative to develop universal vaccines for 'pandemic-prone' viruses such as influenza and ...

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits. The biotech ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

HHS Secretary Robert F. Kennedy Jr. claimed that moving forward, all new vaccines will need to be tested in ...

Eli Lilly CEO David Ricks continued his pushback against the Trump administration's plan to put tariffs on pharmaceutical ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...

Zocdoc launches AI phone assistant 'Zo' for scheduling medical appointments, with CEO Oliver Kharraz saying it's a natural ...

Eli Lilly posted $12.73 billion in revenue in the first quarter, a 45% jump from the prior year, matching the percentage ...

FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two completed postmarketing studies the agency requested more than a decade ago ...